Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose

GWN323, an agonistic human anti‐GITR (glucocorticoid‐induced TNFR‐related protein) IgG1 antibody, was studied clinically as an immuno‐oncology therapeutic agent. A model‐based minimum anticipated biological effect level (MABEL) approach integrating in vitro and in vivo data informed dose selection f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yan, Knee, Deborah, Chen, Xinhui, Dang, Anhthu, Mataraza, Jennifer, Wolf, Babette, Sy, Sherwin K. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468570/
https://www.ncbi.nlm.nih.gov/pubmed/35731955
http://dx.doi.org/10.1111/cts.13355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468570/
https://www.ncbi.nlm.nih.gov/pubmed/35731955
http://dx.doi.org/10.1111/cts.13355

Ejemplares similares